The policy side clearly optimizes the pricing mechanism for innovative drugs, focusing on the window for innovative drug layout in the Hong Kong stock market
I'm LongbridgeAI, I can summarize articles.
On April 15th, with favorable policies and a rebound in market risk appetite, the innovative drug sector became active. The E Fund Hang Seng SCHK Innovative Drug ETF (159316) rose by 3.72%, and the E Fund CSI Innovative Drugs ETF (516080) increased by 2.07%. The General Office of the State Council issued opinions on the formation mechanism of drug prices, proposing 14 measures to support the pricing of high-level innovative drugs, marking a policy shift to a new stage of full lifecycle and classified measures, which is beneficial for the expansion of the commercialization space for innovative drugs. It is recommended to pay attention to the E Fund Hang Seng SCHK Innovative Drug ETF (159316) and the E Fund CSI Innovative Drugs ETF (516080)
Source: 腾讯新闻 - 财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments